Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

Inclusion Criteria: * ≥18 years old * Patients with solid organ malignancy who have received chemotherapy within the past six months. * Clinical and microbiologic relapse of C. difficile associated diarrhea after at least one course of adequate antibiotic therapy or refractory disease that does not respond to treatment. * At least 10 days of vancomycin at least 125mg QID, or metronidazole 500mg TID * C. difficile associated diarrhea is defined as: ≥3 loose or watery stools per day for at least 2 consecutive days or ≥8 loose stools in 48 hours and Positive Clostridium difficile PCR * Life expectancy of \>3 months. Exclusion Criteria: * Expected prolonged compromised immunity * HIV infection with CD4 count \<240 * History of hematopoietic stem cell transplant (HSCT) * Hematologic malignancy * ANC \<1000/mm3 * Contraindications to anesthesia for procedure * Serious cardiopulmonary comorbidities * Inability to tolerate anesthesia * HGB \<8 g/dL * Risk of bleeding during procedure * PLT \<50,000 K/mcL * INR \>1.5 INR * Pregnancy o Pregnant patients will be excluded from this study. * Gastrointestinal (GI) contraindications * Inflammatory bowel disease * Active fistula * Small bowel obstruction * Ileus * Gastroparesis * Nausea and vomiting * Gastrointestinal surgery within the previous 3 months